106-120 of 883
Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
ACC Action CenterLorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
Fluid restriction may not be needed in chronic HF
ACC Action CenterFluid restriction may not be needed in chronic HF
Secondary prevention strategy led by nurses reduces MACE risk after an ACS
ACC Action CenterSecondary prevention strategy led by nurses reduces MACE risk after an ACS
Secondary prevention post-ACS: a nurse-led intervention strategy
ACC Action CenterSecondary prevention post-ACS: a nurse-led intervention strategy
Intensive medical therapy does not reduce MACE risk in women with INOCA
ACC Action CenterIntensive medical therapy does not reduce MACE risk in women with INOCA
- advertisement
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
CardiologyAnalysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
CardiologyEffect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
CardiologyKidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
CardiologyMode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
NYHA FC and Finerenone Response: Clinical Trial Insights
CardiologyNYHA FC and Finerenone Response: Clinical Trial Insights
- advertisement
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
ACC Action CenterSemaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
Ticagrelor antidote restores platelet function in phase 3 study
ACC Action CenterTicagrelor antidote restores platelet function in phase 3 study
Complexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
Heart MattersComplexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
